Skip to main navigation Skip to search Skip to main content

Response to: “Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”

  • Jonathan W. Rick
  • , Peter Lio
  • , Jennifer L. Hsiao
  • , Vivian Y. Shi

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish
Pages (from-to)e33-e34
JournalJournal of the American Academy of Dermatology
Volume87
Issue number1
DOIs
StatePublished - Jul 2022
Externally publishedYes

Cite this